Comparative safety of infliximab and etanercept on the risk of serious infections: does the association vary by patient characteristics?
An increased risk of serious infections associated with infliximab relative to etanercept did not appear to be modified by patients' sex, race/ethnicity, body mass index, or smoking status. There was an indication that the increased risk might be limited to patients<65 years. Additional studies are warranted to verify or refute this finding.
GRo induces anti-inflammatory effects following treatment with LPS via upregulation of HO-1.